These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Protein aggregation and prionopathies. Renner M; Melki R Pathol Biol (Paris); 2014 Jun; 62(3):162-8. PubMed ID: 24698014 [TBL] [Abstract][Full Text] [Related]
24. Influences of intranuclear inclusion on nuclear size - morphometric study on pontine neurons of neuronal intranuclear inclusion disease cases. Uchihara T; Tanaka J; Funata N; Arai K; Hattori T Acta Neuropathol; 2003 Feb; 105(2):103-8. PubMed ID: 12536220 [TBL] [Abstract][Full Text] [Related]
25. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Slow EJ; Graham RK; Hayden MR Trends Genet; 2006 Aug; 22(8):408-11. PubMed ID: 16806565 [TBL] [Abstract][Full Text] [Related]
26. Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease. Sone J; Tanaka F; Koike H; Inukai A; Katsuno M; Yoshida M; Watanabe H; Sobue G Neurology; 2011 Apr; 76(16):1372-6. PubMed ID: 21411744 [TBL] [Abstract][Full Text] [Related]
27. The PML-nuclear inclusion of human supraoptic neurons: a new compartment with SUMO-1- and ubiquitin-proteasome-associated domains. Villagra NT; Navascues J; Casafont I; Val-Bernal JF; Lafarga M; Berciano MT Neurobiol Dis; 2006 Jan; 21(1):181-93. PubMed ID: 16125395 [TBL] [Abstract][Full Text] [Related]
28. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1. Chan WM; Tsoi H; Wu CC; Wong CH; Cheng TC; Li HY; Lau KF; Shaw PC; Perrimon N; Chan HY Hum Mol Genet; 2011 May; 20(9):1738-50. PubMed ID: 21300695 [TBL] [Abstract][Full Text] [Related]
29. Amyloid precursor-like protein 2 cleavage contributes to neuronal intranuclear inclusions and cytotoxicity in spinocerebellar ataxia-7 (SCA7). Takahashi-Fujigasaki J; Breidert T; Fujigasaki H; Duyckaerts C; Camonis JH; Brice A; Lebre AS Neurobiol Dis; 2011 Jan; 41(1):33-42. PubMed ID: 20732423 [TBL] [Abstract][Full Text] [Related]
30. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Arocena DG; Iwahashi CK; Won N; Beilina A; Ludwig AL; Tassone F; Schwartz PH; Hagerman PJ Hum Mol Genet; 2005 Dec; 14(23):3661-71. PubMed ID: 16239243 [TBL] [Abstract][Full Text] [Related]
31. Inclusion-positive cell types in adult-onset intranuclear inclusion body disease: implications for clinical diagnosis. Liu Y; Mimuro M; Yoshida M; Hashizume Y; Niwa H; Miyao S; Ujihira N; Akatsu H Acta Neuropathol; 2008 Dec; 116(6):615-23. PubMed ID: 18923837 [TBL] [Abstract][Full Text] [Related]
32. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Lee VM; Giasson BI; Trojanowski JQ Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877 [TBL] [Abstract][Full Text] [Related]
33. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Hirabayashi M; Inoue K; Tanaka K; Nakadate K; Ohsawa Y; Kamei Y; Popiel AH; Sinohara A; Iwamatsu A; Kimura Y; Uchiyama Y; Hori S; Kakizuka A Cell Death Differ; 2001 Oct; 8(10):977-84. PubMed ID: 11598795 [TBL] [Abstract][Full Text] [Related]
34. Intranuclear immunolocalization of 14-3-3 protein isoforms in brains with spinocerebellar ataxia type 1. Umahara T; Uchihara T; Yagishita S; Nakamura A; Tsuchiya K; Iwamoto T Neurosci Lett; 2007 Mar; 414(2):130-5. PubMed ID: 17224237 [TBL] [Abstract][Full Text] [Related]
35. FUS immunoreactivity of neuronal and glial intranuclear inclusions in intranuclear inclusion body disease. Mori F; Tanji K; Kon T; Odagiri S; Hattori M; Hoshikawa Y; Kono C; Yasui K; Yokoi S; Hasegawa Y; Yoshida M; Wakabayashi K Neuropathol Appl Neurobiol; 2012 Jun; 38(4):322-8. PubMed ID: 21883376 [TBL] [Abstract][Full Text] [Related]
36. Neuronal intranuclear inclusion disease: no longer a pain in the butt. Josephs KA Neurology; 2011 Apr; 76(16):1368-9. PubMed ID: 21411743 [No Abstract] [Full Text] [Related]
37. Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress. Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer. Latonen L Bioessays; 2011 May; 33(5):386-95. PubMed ID: 21425306 [TBL] [Abstract][Full Text] [Related]
38. Rapid flow cytometric measurement of protein inclusions and nuclear trafficking. Whiten DR; San Gil R; McAlary L; Yerbury JJ; Ecroyd H; Wilson MR Sci Rep; 2016 Aug; 6():31138. PubMed ID: 27516358 [TBL] [Abstract][Full Text] [Related]
39. Membrane pores in the pathogenesis of neurodegenerative disease. Kagan BL Prog Mol Biol Transl Sci; 2012; 107():295-325. PubMed ID: 22482454 [TBL] [Abstract][Full Text] [Related]
40. Nucleo-cytoplasmic transport defects and protein aggregates in neurodegeneration. Bitetto G; Di Fonzo A Transl Neurodegener; 2020 Jul; 9(1):25. PubMed ID: 32616075 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]